Durvalumab plus Tremelimumab for the Treatment of Patients (pts) with Advanced Neuroendocrine Neoplasms (NENs) of Lung or Gastroenteropancreatic (GEP) Origin. A Phase II Multicohort Trial (DUNE Trial / GETNE 1601)

被引：0
|
作者：
Hernando-Cubero, J. [1 ]
Manzano, J. L. [2 ]
Benavent, M. [3 ]
Lopez, C. [4 ]
Teule, R. [5 ]
Garcia-Carbonero, R. [6 ]
Carmona-Bayonas, A. [7 ]
Crespo, G. [8 ]
Cubillo, A. [9 ]
Jimenez-Fonseca, P. [10 ]
LaCasta, A. [11 ]
Capdevila, J. [1 ]
机构：
[1] Vall dHebron Univ Hosp, Barcelona, Spain
[2] Inst Catala Oncol Badalona, Barcelona, Spain
[3] Hosp Virgen del Rocio, Seville, Spain
[4] Hosp Univ Marques de Valdecilla, Santander, Spain
[5] Inst Catala Oncol Hosp, Barcelona, Spain
[6] Hosp Univ 12 Octubre, Madrid, Spain
[7] HJM Morales Meseguer, Murcia, Spain
[8] Hosp Univ Burgos, Burgos, Spain
[9] Hosp Univ Madrid Sanchinarro, Madrid, Spain
[10] Hosp Univ Cent Asturias, Oviedo, Spain
[11] Hosp Univ Donostia, San Sebastian, Spain
来源：
NEUROENDOCRINOLOGY | 2018年 / 106卷
关键词：
durvalumab; tremelimumab; neuroendocrine; immunotherapy;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
J10
引用
收藏
页码：228 / 228
页数：1
相关论文
共 50 条
  • [21] PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI plus durvalumab and FOLFIRI plus durvalumab plus tremelimumab in second-line treatment of patients with advanced gastric or gastro-oesophageal junction adenocarcinoma
    Tougeron, D.
    Dahan, L.
    El Hajbi, F.
    Le Malicot, K.
    Evesque, L.
    Aparicio, T.
    Bouche, O.
    Lamichhane, N. Bonichon
    Chibaudel, B.
    Angelergues, A.
    Bodere, A.
    Phelip, J. M.
    Mabro, M.
    Artru, P.
    Louvet, C.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1099 - S1100
  • [22] NICENEC phase 2 trial of nivolumab and platinum-doublet chemotherapy in untreated advanced G3 Neuroendocrine Neoplasms (NENs) of gastroenteropancreatic (GEP) or unknown (UK) origin: Efficacy by differentiation, KI67 index and primary tumor site
    Riesco-Martinez, M. D. C.
    Capdevila, J.
    Alonso, V
    Jimenez-Fonseca, P.
    Teule, A.
    Grande, E.
    Sevilla, I
    Vinuales M, Benavent
    Alonso-Gordoa, T.
    Custodio, A.
    Hernando, J.
    Garcia-Carbonero, R.
    JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 : 190 - 190
  • [23] The PRODIGE 59-DURIGAST trial: A randomized phase II study evaluating FOLFIRI plus durvalumab and FOLFIRI plus durvalumab plus tremelimumab in second-line treatment of patients with advanced gastric or gastro-esophageal junction adenocarcinoma.
    Tougeron, David
    Dahan, Laetitia
    El Hajbi, Farid
    Le Malicot, Karine
    Evesque, Ludovic
    Aparicio, Thomas
    Bouche, Olivier
    Bonichon-Lamichhane, Nathalie
    Chibaudel, Benoist
    Angelergues, Antoine
    Bordere, Anais
    Phelip, Jean-Marc
    Mabro, May
    Artru, Pascal
    Louvet, Christophe
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [24] Final results of the TALENT trial (GETNE1509): a prospective multicohort phase II study of lenvatinib in patients (pts) with G1/G2 advanced pancreatic (panNETs) and gastrointestinal (giNETs) neuroendocrine tumors (NETs).
    Capdevila, Jaume
    Fazio, Nicola
    Lopez, Carlos Lopez
    Teule, Alex
    Valle, Juan W.
    Tafuto, Salvatore
    Custodio, Ana B.
    Reed, Nicholas
    Raderer, Markus
    Grande, Enrique
    Garcia-Carbonero, Rocio
    Jimenez-Fonseca, Paula
    Alonso, Vicente
    Antonuzzo, Lorenzo
    Spallanzani, Andrea
    Berruti, Alfredo
    Sevilla, Isabel
    Munoa, Adelaida La Casta
    Hernando-Cubero, Jorge
    Ibrahim, Toni
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [25] PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI plus Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer
    Evrard, Camille
    Louvet, Christophe
    Hajbi, Farid E. L.
    Fiore, Frederic D., I
    Malicot, Karine L. E.
    Aparicio, Thomas
    Bouche, Olivier
    Laurent-Puig, Pierre
    Bibeau, Frederic
    Lecomte, Thierry
    Lievre, Astrid
    Guimbaud, Rosine
    Kim, Stefano
    Zaanan, Aziz
    Sokol, Harry
    Chibaudel, Benoist
    Desrame, Jerome
    Pierre, Sabrina
    Gonzalez, Daniel
    Lepage, Come
    Tougeron, David
    DIGESTIVE AND LIVER DISEASE, 2021, 53 (04) : 420 - 426
  • [26] Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy (RT) in patients (pts) with localized muscle invasive bladder cancer (MIBC) treated with a selective bladder preservation approach: IMMUNOPRESERVE-SOGUG trial.
    Garcia del Muro, Xavier
    Valderrama, Begona P.
    Medina, Ana
    Andres Cuellar, M.
    Etxaniz, Olatz
    Girones Sarrio, Regina
    Jose Juan-Fita, Maria
    Ferrer, Ferran
    Miras Rodriguez, Isabel
    Lendinez-Cano, Guillermo
    de Haro Piedra, Roberto
    Candal Gomez, Arturo
    Chantada Abal, Venancio
    Salvador Villa, Oscar Buisan
    Luis Pontones, Jose
    Collado, Erica
    Dominguez-Escrig, Jose L.
    Murria, Yashmina
    Vigues, Francesc
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [27] CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC).
    Chen, Eric Xueyu
    Jonker, Derek J.
    Kennecke, Hagen F.
    Berry, Scott R.
    Couture, Felix
    Ahmad, Chaudhary E.
    Goffin, John R.
    Kavan, Petr
    Harb, Mohammed
    Colwell, Bruce
    Samimi, Setareh
    Samson, Benoit
    Abbas, Tahir
    Aucoin, Nathalie
    Aubin, Francine
    Koski, Sheryl L.
    Wei, Alice Chia-chi
    Magoski, Nadine M.
    Tu, Dongsheng
    O'Callaghan, Christopher J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [28] A phase II trial of pemetrexed (P) plus carboplatin (C) in patients (pts) with advanced non-small-cell lung cancer (NSCLC).
    Koshy, S
    Herbst, RS
    Obasaju, CK
    Fossella, F
    Papadimitrakopoulou, V
    Pisters, KMW
    Blumenschein, G
    Peeples, BO
    Hong, WK
    Zinner, RG
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 634S - 634S
  • [29] 177Lu-edotreotide versus everolimus in patients with advanced neuroendocrine tumors of lung or thymic origin: The phase 3 randomized LEVEL, GETNE-T2217 trial.
    Garcia-Alvarez, Alejandro
    Garcia-Carbonero, Rocio
    Anton-Pascual, Beatriz
    Jimenez-Fonseca, Paula
    Llana, Belen
    Pubul, Virginia
    Anido, Urbano
    Molina-Cerrillo, Javier
    del Olmo-Garcia, Maribel
    Teule, Alex
    Vinuales, Marta Benavent
    Taieb, David
    Lepage, Come
    Beron, Amandine
    Ansquer, Catherine
    Deshayes, Emmanuel
    Baudin, Eric
    Haissaguerre, Magalie
    Walter, Thomas
    Capdevila, Jaume
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [30] NEMIO: A randomized phase II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) plus durvalumab plus /- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma
    Thibault, C.
    Audenet, F.
    Borchiellini, D.
    Huillard, O.
    Barthelemy, P.
    Pouessel, D.
    Flechon, A.
    Blons, H.
    Sautes-Fridman, C.
    Sun, C-M.
    Verkarre, V.
    Pallet, N.
    Mejean, A.
    Rouabah, M.
    Helali, I.
    Elaidi, R-T.
    Oudard, S.
    ANNALS OF ONCOLOGY, 2019, 30
12345